NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its second quarter revenues rose 19 percent, driven in part by automated sample-to-answer molecular products sales, which rose 44 percent over the prior-year quarter to $10.7 million from $7.4 million.

For the three months ended June 30, the firm reported total revenues of $76.5 million, up from $64.2 million a year ago, and beating the consensus Wall Street estimate of $75.5 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.